Komori

Astellas Pharma Inc.

4503PharmaceuticalsMega cap
2,491JPY+7.3%
★ Watch (sign-up required)
Price history
¥2,491Latest+40.0%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Astellas Pharma Group consists of the Company, 80 consolidated subsidiaries and 6 equity-method affiliates, and is primarily engaged in the research and development, manufacture and sale of pharmaceuticals. It has a single reportable segment, the pharmaceutical business, with affiliated companies responsible for research and development, manufacturing and sales. The business operates globally, including overseas bases, and the domestic-to-overseas market mix is assessed based on regional revenue data. Major affiliated companies are as follows: - Astellas Pharma Global Development, Inc. (U.S.) — research and development - Astellas Institute for Regenerative Medicine (U.S.) — research and development - Astellas Gene Therapies, Inc. (U.S.) — research and development - Astellas Ireland Co., Ltd. (Ireland) — manufacturing - Astellas Pharma (China) Co., Ltd. (China) — manufacturing - Beijing Astellas Pharmaceutical Co., Ltd. (China) — sales - Astellas Pharma US, Inc. (U.S.) — sales - Astellas Pharma GmbH (Germany) — sales - Beijing Astellas Pharmaceutical Co., Ltd. (China) — sales - Astellas Pharma S.A.S. (France) — sales - Astellas Pharma S.A. (Spain) — sales - Korea Astellas Pharmaceutical Co., Ltd. (South Korea) — sales - 64 other companies (including equity-method affiliates) Key products, including Focus Area and priority strategic products, and their contribution to revenue include PADCEV, IZERVAY, VYLOY, VEOZAH, XOSPATA, XTANDI and other products. The filing includes regional revenue for the fiscal year ending March 2026, total revenue, major customers and management policies relating to sustainability and other matters.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
31.78How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
2.32How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
7.3%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥4.5tnShare price × number of shares. The value of the entire company.
Equity ratio
52.6%The proportion of assets funded by money that does not have to be repaid.
Operating margin
28.8%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
19.6%The average annual growth in sales over the past three years.
What to watch next
Expansion of indications and regional sales growth for key strategic products (PADCEV, IZERVAY, VYLOY, VEOZAH and XOSPATA), including progress toward the target of doubling sales
Impact HighLikelihood Medium
Additional cost optimization from SMT (Sustainable Margin Transformation) and whether improvements in the core profit margin can continue
Impact MediumLikelihood High
Specific implementation details of US drug-pricing policies, including most-favored-nation drug-pricing policies, and their impact on earnings and net realized pricing
Impact HighLikelihood Medium
Progress in pivotal trials for VEOZAH (fezolinetant), including STARLIGHT 2, and regulatory and clinical milestones toward additional indications
Impact MediumLikelihood Medium
Whether additional amortization of intangible assets or impairment losses arise, including a reassessment of post-acquisition PMI and the extent to which monetization is being achieved
Impact HighLikelihood Low
What to watch next
Loading
Who owns itTop holders total 38.9%
Listed holders 38.9%Everyone else 61.1%
The Master Trust Bank of Japan, Ltd. (Trust Account)18.96%
株式会社日本カストディ銀行 (Trust Account)7.19%
Nippon Life Insurance Company2.85%
STATE STREET BANK AND TRUST COMPANY 5012.12%
J.P. Morgan Securities Co., Ltd.1.66%
JP MORGAN CHASE BANK 381.46%
SMBC Nikko Securities Inc.1.24%
野村信託銀行株式会社1.22%
2 other listed holders2.22%
Who owns it
HolderOwnership (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)18.96
株式会社日本カストディ銀行 (Trust Account)7.19
Nippon Life Insurance Company2.85
STATE STREET BANK AND TRUST COMPANY 5012.12
J.P. Morgan Securities Co., Ltd.1.66
JP MORGAN CHASE BANK 381.46
SMBC Nikko Securities Inc.1.24
野村信託銀行株式会社1.22
2 other listed holders2.22
This company's documents
Filings
Timely disclosures
Threads